@misc{10481/64923,
year = {2020},
month = {9},
url = {http://hdl.handle.net/10481/64923},
abstract = {Simple Summary: The application of simultaneous and di erent strategies to treat cancer appears a
promising therapeutic approach. Herein we proposed the application of chemotherapy combined
with a magnetic nanocarrier delivery system to an in vitro and an in vivo experimental mammary
carcinoma model. Drug-loaded biomimetic magnetic nanoparticle can be directed and concentrated
on the tumor cells or site by the apposition of a magnet. Moreover, these nanoparticles can respond
to an alternating magnetic field by developing hyperthermia around 43  C, a temperature at which
tumor cells, but not healthy cells, are particularly sensitive and thus induced to death. Indeed,
when this nanoformulation is injected in vivo in the tumor site, and hyperthermia is generated,
the combined chemo-thermal therapy mediated by these drug-loaded magnetic nanoparticles have
a stronger therapeutic benefit compared to that carried out by the chemotherapeutic alone. These
nanoformulation and strategy are thus promising tools for translational applications in cancer therapy.
Abstract: Biomimetic magnetic nanoparticles mediated by magnetosome proteins (BMNPs) are
potential innovative tools for cancer therapy since, besides being multifunctional platforms, they can be
manipulated by an external gradient magnetic field (GMF) and/or an alternating magnetic field (AMF),
mediating targeting and hyperthermia, respectively. We evaluated the cytocompatibility/cytotoxicity
of BMNPs and Doxorubicin (DOXO)-BMNPs in the presence/absence of GMF in 4T1 and MCF-7
cells as well as their cellular uptake. We analyzed the biocompatibility and in vivo distribution
of BMNPs as well as the e ect of DOXO-BMNPs in BALB/c mice bearing 4T1 induced mammary carcinomas after applying GMF and AMF. Results: GMF enhanced the cell uptake of both BMNPs and
DOXO-BMNPs and the cytotoxicity of DOXO-BMNPs. BMNPs were biocompatible when injected
intravenously in BALB/c mice. The application of GMF on 4T1 tumors after each of the repeated
(6 ) iv administrations of DOXO-BMNPs enhanced tumor growth inhibition when compared to
any other treatment, including that with soluble DOXO. Moreover, injection of DOXO-BMNPs in
the tumor combined with application of an AMF resulted in a significant tumor weight reduction.
These promising results show the suitability of BMNPs as magnetic nanocarriers for local targeted
chemotherapy and as local agents for hyperthermia.},
organization = {Spanish Government

RYC-2014-16901},
organization = {Junta de Andalucía, Programa Operativo FEDER 2014-2020 	
A1-FQM-341-UGR18
C-FQM-497-UGR18},
organization = {Progetto di Ricerca Fondi di Ateneo per la Ricerca-FAR 2017 "Development of innovative biological materials for the functional regeneration of cardiac tissue models"},
organization = {Ministerio de Economia y Competitividad from Spain 	
CGL2016-76723},
organization = {European Union (EU)},
organization = {Junta de Andalucía

A-BIO-376-UGR18},
organization = {Unidad Científica de Excelencia of the University of Granada 	
UCE-PP2016-05},
organization = {Ministry of Economy and Competitiveness, Spain 	
EST2019-013134-I
EEBB-I-17-12558 58},
publisher = {Mdpi},
keywords = {Magnetic nanoparticles},
keywords = {Tumor targeting},
keywords = {Cytotoxicity},
keywords = {Doxorubicin},
keywords = {Hyperthermia},
title = {Biomimetic Magnetite Nanoparticles as Targeted Drug Nanocarriers and Mediators of Hyperthermia in an Experimental Cancer Model},
doi = {10.3390/cancers12092564},
author = {Oltolina, Francesca and Peigneux, Ana and Iglesias Salto, Guillermo Ramón and Jiménez López, Concepción},
}